The cost-effectiveness of autologous peripheral blood stem cell transplantation (PBSCT) compared with autologous bone marrow transplantation (ABMT) for refractory or relapsed non-Hodgkin's lymphoma (NHL) or Morbus Hodgkin (MH) was assessed. Costs were determined from the induction chemotherapy regimen up to 3 months after discharge from hospital following the transplantation. Quality of life was measured by the EuroQol, the Rotterdam Symptom Checklist (RSCL) and the SF-36. Patients were randomised according to a 2:1 ratio to undergo either PBSCT or ABMT. 62 patients underwent PBSCT and 29 ABMT. Costs of the transplantation period were significantly lower in the PBSCT group (15 008 Euros) than in the ABMT group (19 000 Euros). Significant differences in quality of life were all in favour of PBSCT and emerged using the RSCL, both on 14 days after the transplantation and three months after discharge. We conclude that PBSCT is associated with lower costs and a better quality of life than ABMT for patients with refractory or relapsed NHL or MH.

Adjuvant chemotherapy, Bone marrow transplantation, Cost-benefit analysis, Costs and cost analysis, Haematopoietic stem cell transplantation, Hodgkin's disease, Non-Hodgkin's lymphoma, Quality of life, Recurrence
dx.doi.org/10.1016/S0959-8049(01)00198-8, hdl.handle.net/1765/63911
European Journal of Cancer
Erasmus School of Health Policy & Management (ESHPM)

van Agthoven, M, Vellenga, E, Fibbe, W.E, Kingma, T, & Uyl-de Groot, C.A. (2001). Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease: A prospective randomised trial. European Journal of Cancer, 37(14), 1781–1789. doi:10.1016/S0959-8049(01)00198-8